Purple Biotech (Israel) Investor Sentiment

KTOV Stock  ILA 11.00  1.90  14.73%   
About 62% of Purple Biotech's investor base is looking to short. The analysis of current outlook of investing in Purple Biotech suggests that many traders are alarmed regarding Purple Biotech's prospects. The current market sentiment, together with Purple Biotech's historical and current headlines, can help investors time the market. In addition, many technical investors use Purple Biotech stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at news.google.com         
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Encouraging Early Data For Biotechs Cancer Therapies Research Report - Streetwise Reports
Google News at Macroaxis
over a year ago at news.google.com         
Can Purple Biotech Afford To Invest In Growth - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
What is the Markets View on Purple Biotech Ltd - ADR Stocks Price and Volume Trends Tuesday - Invest...
Google News at Macroaxis
over a year ago at news.google.com         
Purple Biotech Reports Positive Interim and Preliminary Results ... - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
GVAX Cancer Vaccine Plus Nivolumab and Urelumab Elicits Early ... - OncLive
Google News at Macroaxis
over a year ago at news.google.com         
Henrietta Lacks family settles lawsuit with a biotech company that used her cells without consent - ...
Google News at Macroaxis
over a year ago at news.google.com         
McDonalds Earnings Grimace Shake Boosts Sales at Burger Chain ... - The Wall Street Journal
Google News at Macroaxis
over a year ago at news.google.com         
Korro Bio absorbs Frequency Therapeutics in reverse biotech merger - The Boston Globe
Google News at Macroaxis
over a year ago at news.google.com         
Aslan hopes to take on Dupixent in AD with fewer side effects - FierceBiotech
Google News at Macroaxis
over a year ago at news.google.com         
Takeda adds another F-Star collab to constellation, this time for 1B ... - FierceBiotech
Google News at Macroaxis
over a year ago at news.google.com         
US approves chicken made from cultivated cells, the nations first lab-grown meat - CIProud.com
Google News at Macroaxis
over a year ago at news.google.com         
Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for ... - Journal of Translational Medi...
Google News at Macroaxis
over a year ago at news.google.com         
New RNA biotech raises 300M in largest private round of 2023 - FierceBiotech
Google News at Macroaxis
over a year ago at news.google.com         
Siren emerges from stealth with plans to marry gene therapy to ... - BioPharma Dive
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Purple Biotech that are available to investors today. That information is available publicly through Purple media outlets and privately through word of mouth or via Purple internal channels. However, regardless of the origin, that massive amount of Purple data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Purple Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Purple Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Purple Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Purple Biotech alpha.

Purple Biotech Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Purple Stock analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals